Drug-Induced Liver Injury Clinical Trial
— PAINOfficial title:
Pharmacogenomics of APAP Induced DILI in Chinese Population.
Acetaminophen (APAP) is the most commonly used NSAIDS in clinic, and it is also a common cause of drug-induced liver injury (DILI). In 2012, the proportion of DILI caused by APAP in the United States was 51%, while in Asia, it was only 7.10%. Previously, a small cohort study in the United States screened for some of the susceptibility genes for DILI due to APAP by the Genome wide association study (GWAS) method. However, the genetic susceptibility loci based on the US cohort were not applicable to the Chinese population. Therefore, we make a study design include Chinese population who ingested APAP and divided them into case group and control group according to the occurrence of DILI. We hope to be able to find the root of differences at the genetic level and explore new pathogenic mechanisms.
Status | Recruiting |
Enrollment | 339 |
Est. completion date | August 31, 2025 |
Est. primary completion date | August 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years and older |
Eligibility | Inclusion criteria: - A clear history of acetaminophen (or acetaminophen-containing drugs) ingestion. - Plasma and/or urine testing for acetaminophen components if history of ingestion is unclear. - Monitoring of Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) = 1000 IU/L at any time after APAP administration and Roussel Uclaf Causality Assessment Method(RUCAM) score > 6 - Age = 14 years old - The subject or guardian agrees to participate in this project and signs an informed consent form. Exclusion criteria: - The use of drugs for which frequency of adverse reactions to liver damage is defined as "common or very common" (=1%) in the instructions. - Concurrent use of herbs that are clearly susceptible to liver damage (see list of definitions in the Annex). - Have a known definite cause of liver damage: active viral hepatitis; alcoholic liver disease; autoimmune liver disease; primary or secondary liver tumors; and other underlying liver disease that has affected liver function. - Those who fail to provide complete general information and clinical information. - Subjects or guardians who do not agree to see this project do not sign the informed consent form. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital with Nanjing Medical University | Nanjing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
The First Affiliated Hospital with Nanjing Medical University | Beijing Genomics Institute, Nanjing Medical University, University of Colorado, Denver |
China,
Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007 Nov;102(11):2459-63. Epub 2007 Jun 29. Erratum in: Am J Gastroenterol. 2008 Jan;103(1):255. — View Citation
Chiew AL, Reith D, Pomerleau A, Wong A, Isoardi KZ, Soderstrom J, Buckley NA. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust. 2020 Mar;212(4):175-183. doi: 10.5694/mja2.50428. Epub 2019 Dec 1. Review. — View Citation
Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015 Dec 24;17(1). pii: E14. doi: 10.3390/ijms17010014. Review. — View Citation
Lammers LA, Achterbergh R, Pistorius MC, Romijn JA, Mathôt RA. Quantitative Method for Simultaneous Analysis of Acetaminophen and 6 Metabolites. Ther Drug Monit. 2017 Apr;39(2):172-179. doi: 10.1097/FTD.0000000000000373. — View Citation
Leventhal TM, Gottfried M, Olson JC, Subramanian RM, Hameed B, Lee WM; Acute Liver Failure Study Group. Acetaminophen is Undetectable in Plasma From More Than Half of Patients Believed to Have Acute Liver Failure Due to Overdose. Clin Gastroenterol Hepatol. 2019 Sep;17(10):2110-2116. doi: 10.1016/j.cgh.2019.01.040. Epub 2019 Feb 5. — View Citation
Major JM, Zhou EH, Wong HL, Trinidad JP, Pham TM, Mehta H, Ding Y, Staffa JA, Iyasu S, Wang C, Willy ME. Trends in rates of acetaminophen-related adverse events in the United States. Pharmacoepidemiol Drug Saf. 2016 May;25(5):590-8. doi: 10.1002/pds.3906. Epub 2015 Nov 3. — View Citation
Monte AA, Sonn B, Saben J, Rumack BH, Reynolds KM, Dart RC, Heard KJ. The Genomics of Elevated ALT and Adducts in Therapeutic Acetaminophen Treatment: a Pilot Study. J Med Toxicol. 2021 Apr;17(2):160-167. doi: 10.1007/s13181-020-00815-2. Epub 2020 Oct 13. — View Citation
Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988 Dec 15;319(24):1557-62. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | genetic polymorphism | the genetic polymorphism(HLA?SNPs )frequency difference between case and control groups | 2 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05517668 -
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
|
Phase 2 | |
Recruiting |
NCT05060289 -
A Prognostic Model for Drug-induced Liver Injury in China
|
||
Completed |
NCT03092817 -
Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
|
Phase 3 | |
Completed |
NCT03211208 -
Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients
|
||
Completed |
NCT02182167 -
A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02061826 -
Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA)
|
N/A | |
Completed |
NCT03665402 -
A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
|
N/A | |
Not yet recruiting |
NCT03091218 -
Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule.
|
N/A | |
Not yet recruiting |
NCT03060252 -
Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill
|
N/A | |
Not yet recruiting |
NCT03091244 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule.
|
N/A | |
Not yet recruiting |
NCT03091556 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill.
|
N/A | |
Not yet recruiting |
NCT03091608 -
Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule
|
N/A | |
Completed |
NCT02407964 -
A Retrospective Study on Drug Induced Liver Injury in China
|
N/A | |
Active, not recruiting |
NCT05144217 -
Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
|
Phase 2/Phase 3 | |
Completed |
NCT01705041 -
Preliminary Evaluation of a Point-Of-Care Liver Function Test
|
N/A | |
Recruiting |
NCT02086708 -
Ultrasound Method to Measure Fibrosis of the Liver in Children
|
N/A | |
Recruiting |
NCT05465642 -
Alterations of Gut Microbiota and Serum Biochemical Markers in DILI Patients
|
||
Completed |
NCT01434173 -
Risk of Acute Liver Injury in Users of Antimicrobials
|
N/A | |
Completed |
NCT05532345 -
Discrimination of DILI and AIH by Artificial Intelligence
|
||
Completed |
NCT03602703 -
Immune Responses in Hepatocellular Carcinoma Patients After Treatment With Direct Acting Antiviral Drugs
|